TEVA

Teva Pharmaceutical Industries Limited · NYSE · Healthcare · USD · 10-K for 2025, filed 2026-02-03

Figures on this page computed 2026-11-08 13:37 UTC

Last close

41.85USD

Market data, 2026-11-04

TEVA: weekly closes from 36.77 on 2026-08-14 to 41.85 on 2026-11-04, a move of +13.8%. Prices in USD.

Weekly closes, 2026-08-14 to 2026-11-04

Over that span: +13.8%

Except where said otherwise: 10-K for 2025, filed 2026-02-03

34.6xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-03
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- 10-K for 2025, filed 2026-02-03
- 10-K for 2025, filed 2026-02-03
- 10-K for 2025, filed 2026-02-03
- 10-Q for 2025, filed 2026-11-03
- 10-K for 2025, filed 2026-02-03
- 10-Q for 2025, filed 2026-11-03
The filing itself
8.2%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- 10-K for 2025, filed 2026-02-03
- 10-K for 2025, filed 2026-02-03
The filing itself
6.7%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- 10-K for 2025, filed 2026-02-03
- 10-K for 2025, filed 2026-02-03
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- 10-K for 2025, filed 2026-02-03
- 10-Q for 2025, filed 2026-11-03
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Safety is the furthest below its sector's middle: 0.29 against 0.53 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.98x

-0.54x

1.04x

0.27x

2.47x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-02-03

Sales0.98x
Its own average over 10 years, 17.66B.
Profit-0.54x
Its own average over 10 years, -2.59B.
Free cash flow1.04x
Its own average over 10 years, 1.10B.
Debt0.27x
Its own average over 10 years, 9.02B.
Price2.47x
Its own average over 11 years, 17. Market data, 2026-11-04

Profit is furthest from its own average, at -0.54 times.

The filed years, as a table

Each line is 100 at 2016-12-31, the first year we hold.

Filed year	Sales	Profit	Shares in issue
2016-12-31	100.0	100.0	100.0
2017-12-31	102.2	-4,943.8	105,723,205.0
2018-12-31	83.4	-653.5	106,243,496.4
2019-12-31	77.1	-303.6	113,527,575.4
2020-12-31	76.1	-1,212.8	113,943,808.5
2021-12-31	72.5	126.7	115,192,507.8
2022-12-31	68.1	-743.5	115,504,682.6
2023-12-31	72.3	-169.9	116,441,207.1
2024-12-31	75.5	-498.2	117,689,906.3
2025-12-31	78.8	428.6	121,019,771.1

How sales was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001193125-26-034532
Reported in: USD

The filing itself

How profit was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001193125-26-034532
Reported in: USD

The filing itself

How shares in issue was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001193125-26-034532
Reported in: USD

The filing itself

Figures behind the shape

Growth

0.7%

faster is higher, placed against 4,950 companies as of 2026-11-07

Five-year revenue growth rate0.7%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
One-year change in net income186.0%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Returns on capital

17.8%

higher is higher, placed against 5,089 companies as of 2026-11-07

Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- 10-K for 2025, filed 2026-02-03
- 10-K for 2025, filed 2026-02-03
- 10-K for 2025, filed 2026-02-03
- 10-Q for 2025, filed 2026-11-03
- 10-K for 2025, filed 2026-02-03
- 10-Q for 2025, filed 2026-11-03
The filing itself
Return on equity17.8%
Net Income / Shareholders' Equity x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- 10-K for 2025, filed 2026-02-03
- 10-Q for 2025, filed 2026-11-03
The filing itself
Return on assets3.5%
Net Income / Total Assets x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- 10-K for 2025, filed 2026-02-03
- 10-Q for 2025, filed 2026-11-03
The filing itself

Margins

51.8%

wider is higher, placed against 3,412 companies as of 2026-11-07

Gross margin51.8%
Gross Profit / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- 10-K for 2025, filed 2026-02-03
- 10-K for 2025, filed 2026-02-03
The filing itself
Operating margin12.5%
Operating Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- 10-K for 2025, filed 2026-02-03
- 10-K for 2025, filed 2026-02-03
The filing itself
Net margin8.2%
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- 10-K for 2025, filed 2026-02-03
- 10-K for 2025, filed 2026-02-03
The filing itself
Free cash flow margin6.7%
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- 10-K for 2025, filed 2026-02-03
- 10-K for 2025, filed 2026-02-03
The filing itself

Price

34.6x

cheaper is higher, placed against 4,362 companies as of 2026-11-07

Price to earnings34.6x
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-03
The filing itself
Price to book6.3x10-Q for 2025, filed 2026-11-03
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Fiscal year
2025
Accession
0000818686-26-000006
Reported in
USD
- computed
- 10-Q for 2025, filed 2026-11-03
- computed
- 10-K for 2025, filed 2026-02-03
The filing itself
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-03
- 10-K for 2025, filed 2026-02-03
- 10-Q for 2025, filed 2026-11-03
- 10-K for 2025, filed 2026-02-03
The filing itself
Price to sales ratio2.9x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-03
- 10-K for 2025, filed 2026-02-03
The filing itself

Safety

1.04

safer is higher, placed against 3,227 companies as of 2026-11-07

Debt to equityn/a
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- 10-K for 2025, filed 2026-02-03
- 10-Q for 2025, filed 2026-11-03
The filing itself
Current ratio1.0410-Q for 2025, filed 2026-11-03
Current Assets / Current Liabilities
Source
computed
Fiscal year
2025
Accession
0000818686-26-000006
Reported in
USD
- 10-Q for 2025, filed 2026-11-03
- 10-Q for 2025, filed 2026-11-03
The filing itself
Interest coverage2.4x
Operating Income / Interest Expense
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- 10-K for 2025, filed 2026-02-03
- 10-K for 2025, filed 2026-02-03
The filing itself
Altman Z-Score1.05
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
USD
- Computed from the 10-K for 2025, filed 2026-02-03
- Computed from the 10-K for 2025, filed 2026-02-03
- Computed from the 10-K for 2025, filed 2026-02-03
- Computed from the 10-K for 2025, filed 2026-02-03
- Computed from the 10-K for 2025, filed 2026-02-03

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- 10-K for 2025, filed 2026-02-03
- Computed from the 10-K for 2025, filed 2026-02-03
- 10-K for 2025, filed 2026-02-03
The filing itself
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.